Bio-Rad vs. Charles River Labs: Which Medical Research Stock Is a Better Buy in 2026?
Bio-Rad posts robust margins and liquidity, while Charles River leads in global drug discovery services. Explore how their fundamentals stack up for investors.
Bio-Rad vs. Charles River Labs: Which Medical Research Stock Is a Better Buy in 2026?
Overview
Is your portfolio better served by a diagnostic equipment leader or a pharmaceutical research titan? Deciding between Bio-Rad Laboratories (NYSE:BIO) and Charles River Laboratories International (NYSE:CRL) requires weighing specialized equipment against clinical services.
Bio-Rad provides essential instruments and reagents used in labs worldwide, while Charles River offers critical research models and services for drug discovery. Investors often compare these two because they both occupy vital, non-discretionary positions within the biotechnology and pharmaceutical supply chains.
Details
Bio-Rad Laboratories develops and markets products for life science research and clinical diagnostics. It serves a diverse customer base including researchers, clinicians, and scientists across the healthcare stocks, food science, and public health markets. The company maintains a global presence, with roughly 7,450 employees across 37 countries supporting its dual-segment business model.
Source
Originally published at www.fool.com.
